Progressive publishes new research

/**/

RNS Number : 3217M Watkin Jones plc 19 December 2025  

  Watkin Jones   New Progressive research note   Progressive Equity Research has been commissioned by Watkin Jones to produce ongoing research coverage.  A new research document has been published this morning, and is freely available to UK investors.      Research note summary: Earnings beat estimates after 'resilient' FY25

Watkin Jones this week delivered adjusted PBT of £5.6m for the 12 months to 30 September, ahead of our estimate of £5.0m and down from a prior-year result of £9.2m, reflecting the 'challenging backdrop over the last three years'. Net cash before leases declined from £83.4m to £70.5m, in line with our estimates. We introduce FY26E forecasts, conservatively pointing to a 20% rise in adjusted PBT to £6.8m and further growth in net cash.

      Click here for full analysis

  Subscribe to Progressive's research, which is freely available to every type of investor, and be kept informed about our regular programme of investor engagement.        About Progressive: Progressive is an equity research and investor engagement company.  FCA authorised and regulated, the firm has a 15-strong team of highly experienced analysts.  We provide Institutional grade research and connect companies with investors across every sector of the market.   www.progressive-research.com   For further information please contact:  +44 (0) 20 7781 5300 info@progressive-research.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.  END  NRATLBBTMTABBRA